Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population

doi:10.1056/NEJMoa041534

Volume 352:1769-1778		April 28, 2005		Number 17

Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population

Paul C. Adams, M.D., David M. Reboussin, Ph.D., James C. Barton, M.D., Christine E. McLaren, Ph.D., John H. Eckfeldt, M.D., Ph.D., Gordon D. McLaren, M.D., Fitzroy W. Dawkins, M.D., Ronald T. Acton, Ph.D., Emily L. Harris, Ph.D., M.P.H., Victor R. Gordeuk, M.D., Catherine Leiendecker-Foster, M.S., Mark Speechley, Ph.D., Beverly M. Snively, Ph.D., Joan L. Holup, M.A., Elizabeth Thomson, M.S., R.N., Phyliss Sholinsky, M.S.P.H., for the Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators

Full Text

PDF

PDA Full Text

PowerPoint Slide Set

Perspective
by Fleming, R. E.

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

PubMed Citation

ABSTRACT

Background Iron overload and hemochromatosis are common, treatableconditions. HFE genotypes, levels of serum ferritin, transferrinsaturation values, and self-reported medical history were studiedin a multiethnic primary care population.

Methods Participants were recruited from primary care practicesand blood-drawing laboratories. Blood samples were tested fortransferrin saturation, serum ferritin, and C282Y and H63D mutationsof the HFE gene. Before genetic screening, participants wereasked whether they had a history of medical conditions relatedto iron overload.

Results Of the 99,711 participants, 299 were homozygous forthe C282Y mutation. The estimated prevalence of C282Y homozygoteswas higher in non-Hispanic whites (0.44 percent) than in NativeAmericans (0.11 percent), Hispanics (0.027 percent), blacks(0.014 percent), Pacific Islanders (0.012 percent), or Asians(0.000039 percent). Among participants who were homozygous forthe C282Y mutation but in whom iron overload had not been diagnosed(227 participants), serum ferritin levels were greater than300 µg per liter in 78 of 89 men (88 percent) and greaterthan 200 µg per liter in 79 of 138 women (57 percent).Pacific Islanders and Asians had the highest geometric meanlevels of serum ferritin and mean transferrin saturation despitehaving the lowest prevalence of C282Y homozygotes. There were364 participants in whom iron overload had not been diagnosed(29 C282Y homozygotes) who had a serum ferritin level greaterthan 1000 µg per liter. Among men, C282Y homozygotes andcompound heterozygotes were more likely to report a historyof liver disease than were participants without HFE mutations.

Conclusions The C282Y mutation is most common in whites, andmost C282Y homozygotes have elevations in serum ferritin levelsand transferrin saturation. The C282Y mutation does not accountfor high mean serum ferritin levels and transferrin saturationvalues in nonwhites.

Source Information

From the Department of Medicine, London Health Sciences Centre, London, Ont., Canada (P.C.A.); the Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, N.C. (D.M.R., B.M.S.); Southern Iron Disorders Center, Birmingham, Ala. (J.C.B.); Epidemiology Division (C.E.M.) and Division of Hematology and Oncology (G.D.M.), Department of Medicine, University of California, Irvine; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis (J.H.E., C.L.-F.); Veterans Affairs Long Beach Healthcare System, Long Beach, Calif. (G.D.M.); Department of Medicine, Howard University, Washington, D.C. (F.W.D., V.R.G.); Departments of Microbiology, Medicine, and Epidemiology and International Health, University of Alabama at Birmingham, Birmingham (R.T.A.); Kaiser Permanente Center for Health Research, Portland, Oreg. (E.L.H.), Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada (M.S.); Kaiser Permanente Center for Health Research, Honolulu (J.L.H.); National Human Genome Research Institute, Bethesda, Md. (E.T.); and the Epidemiology and Biometry Program, National Heart, Lung, and Blood Institute, Bethesda, Md. (P.S.).

Address reprint requests to Dr. Adams at the Department of Medicine, London Health Sciences Centre, 339 Windermere Rd., London, ON N6A 5A5, Canada, or at padams{at}uwo.ca.

Full Text of this Article

This article has been cited by other articles:

Solanas-Barca, M., Mateo-Gallego, R., Calmarza, P., Jarauta, E., Bea, A. M., Cenarro, A., Civeira, F. (2009). Mutations in HFE Causing Hemochromatosis Are Associated with Primary Hypertriglyceridemia. J. Clin. Endocrinol. Metab. 94: 4391-4397 [Abstract] [Full Text]
Barton, J. C., Leiendecker-Foster, C., Li, H., DelRio-LaFreniere, S., Acton, R. T., Eckfeldt, J. H., for the HEIRS Study, (2009). HAMP promoter mutation nc.-153C>T in 785 HEIRS Study participants. haematol 94: 1465-1465 [Full Text]
Queiroz-Andrade, M., Blasbalg, R., Ortega, C. D., Rodstein, M. A. M., Baroni, R. H., Rocha, M. S., Cerri, G. G. (2009). MR Imaging Findings of Iron Overload. RadioGraphics 29: 1575-1589 [Abstract] [Full Text]
Valenti, L., Girelli, D., Valenti, G. F., Castagna, A., Como, G., Campostrini, N., Rametta, R., Dongiovanni, P., Messa, P., Fargion, S. (2009). HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. CJASN 4: 1331-1337 [Abstract] [Full Text]
Rogowski, W. H. (2009). The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study. Med Decis Making 29: 224-238 [Abstract]
Oettl, T., Dickenmann, M. (2009). Haemochromatosis in end-stage renal disease: when waste is a treatment option. NDT Plus 2: 43-45 [Abstract] [Full Text]
Adams, P. C., Pankow, J. S., Barton, J. C., Acton, R. T., Leiendecker-Foster, C., McLaren, G. D., Speechley, M., Eckfeldt, J. H. (2009). HFE C282Y Homozygosity Is Associated With Lower Total and Low-Density Lipoprotein Cholesterol: The Hemochromatosis and Iron Overload Screening Study. Circ Cardiovasc Genet 2: 34-37 [Abstract] [Full Text]
Zimmermann, M. B, Fucharoen, S., Winichagoon, P., Sirankapracha, P., Zeder, C., Gowachirapant, S., Judprasong, K., Tanno, T., Miller, J. L, Hurrell, R. F (2008). Iron metabolism in heterozygotes for hemoglobin E (HbE), {alpha}-thalassemia 1, or {beta}-thalassemia and in compound heterozygotes for HbE/{beta}-thalassemia. Am. J. Clin. Nutr. 88: 1026-1031 [Abstract] [Full Text]
van der A, D. L., Rovers, M. M., Grobbee, D. E., Marx, J. J.M., Waalen, J., Ellervik, C., Nordestgaard, B. G., Olynyk, J. K., Mills, P. R., Shepherd, J., Grandchamp, B., Boer, J. M.A., Caruso, C., Arca, M., Meyer, B. J., van der Schouw, Y. T. (2008). Mutations in the HFE Gene and Cardiovascular Disease Risk: An Individual Patient Data Meta-Analysis of 53 880 Subjects. Circ Cardiovasc Genet 1: 43-50 [Abstract] [Full Text]
Nagayoshi, Y., Nakayama, M., Suzuki, S., Hokamaki, J., Shimomura, H., Tsujita, K., Fukuda, M., Yamashita, T., Nakamura, Y., Sugiyama, S., Ogawa, H. (2008). A Q312X mutation in the hemojuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis. Eur J Heart Fail 10: 1001-1006 [Abstract] [Full Text]
Phatak, P. D., Bonkovsky, H. L., Kowdley, K. V. (2008). Hereditary Hemochromatosis: Time for Targeted Screening. ANN INTERN MED 149: 270-272 [Abstract] [Full Text]
Waalen, J., Beutler, E., Rienhoff, H. Y. Jr., Allen, K. J., Gurrin, L., Powell, L. (2008). Iron-Overload-Related Disease in HFE Hereditary Hemochromatosis. NEJM 358: 2293-2295 [Full Text]
Wood, M. J., Powell, L. W., Ramm, G. A. (2008). Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 111: 4456-4462 [Abstract] [Full Text]
Barton, J. C. (2008). Ferritin >1000: grand for hemochromatosis screening?. Blood 111: 3309-3309 [Full Text]
Waalen, J., Felitti, V. J., Gelbart, T., Beutler, E. (2008). Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 111: 3373-3376 [Abstract] [Full Text]
Valenti, L., Dongiovanni, P., Fracanzani, A. L., Fargion, S. (2008). Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of HFE Gene Mutations: Response to Equitani et al.. Diabetes Care 31: e18-e18 [Full Text]
Allen, K. J., Gurrin, L. C., Constantine, C. C., Osborne, N. J., Delatycki, M. B., Nicoll, A. J., McLaren, C. E., Bahlo, M., Nisselle, A. E., Vulpe, C. D., Anderson, G. J., Southey, M. C., Giles, G. G., English, D. R., Hopper, J. L., Olynyk, J. K., Powell, L. W., Gertig, D. M. (2008). Iron-Overload-Related Disease in HFE Hereditary Hemochromatosis. NEJM 358: 221-230 [Abstract] [Full Text]
Bacon, B. R., Britton, R. S. (2008). Clinical Penetrance of Hereditary Hemochromatosis. NEJM 358: 291-292 [Full Text]
Cazzola, M., Della Porta, M. G., Malcovati, L. (2008). Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes. ASH Education Book 2008: 166-175 [Abstract] [Full Text]
Arredondo, M., Jorquera, D., Carrasco, E., Albala, C., Hertrampf, E. (2007). Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with iron status in persons with type 2 diabetes mellitus. Am. J. Clin. Nutr. 86: 1347-1353 [Abstract] [Full Text]
Swaminathan, S., Fonseca, V. A., Alam, M. G., Shah, S. V. (2007). The Role of Iron in Diabetes and Its Complications. Diabetes Care 30: 1926-1933 [Full Text]
Harris, E. L., McLaren, C. E., Reboussin, D. M., Gordeuk, V. R., Barton, J. C., Acton, R. T., McLaren, G. D., Vogt, T. M., Snively, B. M., Leiendecker-Foster, C., Holup, J. L., Passmore, L. V., Eckfeldt, J. H., Lin, E., Adams, P. C. (2007). Serum Ferritin and Transferrin Saturation in Asians and Pacific Islanders. Arch Intern Med 167: 722-726 [Abstract] [Full Text]
Sutedja, N. A., Sinke, R. J., Van Vught, P. W. J., Van der Linden, M. W., Wokke, J. H. J., Van Duijn, C. M., Njajou, O. T., Van der Schouw, Y. T., Veldink, J. H., Van den Berg, L. H. (2007). The Association Between H63D Mutations in HFE and Amyotrophic Lateral Sclerosis in a Dutch Population. Arch Neurol 64: 63-67 [Abstract] [Full Text]
Lehmann, D J, Worwood, M, Ellis, R, Wimhurst, V L J, Merryweather-Clarke, A T, Warden, D R, Smith, A D, Robson, K J H (2006). Iron genes, iron load and risk of Alzheimer's disease.. J. Med. Genet. 43: e52-e52 [Abstract] [Full Text]
Acton, R. T., Barton, J. C., Passmore, L. V., Adams, P. C., Speechley, M. R., Dawkins, F. W., Sholinsky, P., Reboussin, D. M., McLaren, G. D., Harris, E. L., Bent, T. C., Vogt, T. M., Castro, O. (2006). Relationships of Serum Ferritin, Transferrin Saturation, and HFE Mutations and Self-Reported Diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.. Diabetes Care 29: 2084-2089 [Abstract] [Full Text]
Whitlock, E. P., Garlitz, B. A., Harris, E. L., Beil, T. L., Smith, P. R. (2006). Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force.. ANN INTERN MED 145: 209-223 [Abstract] [Full Text]
Vantyghem, M.-C., Fajardy, I., Dhondt, F., Girardot, C., D'Herbomez, M., Danze, P.-M., Rousseaux, J., Wemeau, J.-L. (2006). Phenotype and HFE genotype in a population with abnormal iron markers recruited from an Endocrinology Department.. Eur J Endocrinol 154: 835-841 [Abstract] [Full Text]
Swinkels, D. W., Janssen, M. C.H., Bergmans, J., Marx, J. J.M. (2006). Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches. Clin. Chem. 52: 950-968 [Abstract] [Full Text]
Bhavnani, M, Lloyd, D, Marples, J, Pendry, K, Worwood, M (2006). Targeted screening for genetic haemochromatosis: a combined phenotype/genotype approach.. J. Clin. Pathol. 59: 501-504 [Abstract] [Full Text]
McCune, C A, Ravine, D, Carter, K, Jackson, H A, Hutton, D, Hedderich, J, Krawczak, M, Worwood, M (2006). Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 55: 554-562 [Abstract] [Full Text]
Bacon, B. R. (2006). Screening for Hemochromatosis. Arch Intern Med 166: 269-270 [Full Text]
Powell, L. W., Dixon, J. L., Ramm, G. A., Purdie, D. M., Lincoln, D. J., Anderson, G. J., Subramaniam, V. N., Hewett, D. G., Searle, J. W., Fletcher, L. M., Crawford, D. H., Rodgers, H., Allen, K. J., Cavanaugh, J. A., Bassett, M. L. (2006). Screening for hemochromatosis in asymptomatic subjects with or without a family history.. Arch Intern Med 166: 294-301 [Abstract] [Full Text]
Hahn, J.-U., Steiner, M., Bochnig, S., Schmidt, H., Schuff-Werner, P., Kerner, W. (2006). Evaluation of a Diagnostic Algorithm for Hereditary Hemochromatosis in 3,500 Patients With Diabetes. Diabetes Care 29: 464-466 [Full Text]
Camaschella, C. (2005). Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106: 3710-3717 [Abstract] [Full Text]
Qaseem, A., Aronson, M., Fitterman, N., Snow, V., Weiss, K. B., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee, (2005). Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED 143: 517-521 [Abstract] [Full Text]
Schmitt, B., Golub, R. M., Green, R. (2005). Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians. ANN INTERN MED 143: 522-536 [Abstract] [Full Text]
(2005). Hemochromatosis and Iron Overload in a Diverse Primary-Care Population. JWatch Gastroenterology 2005: 4-4 [Full Text]
Adams, P. C., Reboussin, D. M., Leiendecker-Foster, C., Moses, G. C., McLaren, G. D., McLaren, C. E., Dawkins, F. W., Kasvosve, I., Acton, R. T., Barton, J. C., Zaccaro, D., Harris, E. L., Press, R., Chang, H., Eckfeldt, J. H. (2005). Comparison of the Unsaturated Iron-Binding Capacity with Transferrin Saturation as a Screening Test to Detect C282Y Homozygotes for Hemochromatosis in 101 168 Participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Clin. Chem. 51: 1048-1052 [Full Text]
(2005). Hemochromatosis in Diverse Populations. JWatch General 2005: 3-3 [Full Text]

Comments and questions? Please contact us.